Table 1.
Characteristics | ||
Enrolled patients | 262 | |
Age (yr) | Median (range) | 70 (32-92) |
Sex | Male/female | 176/86 |
Etiology | HBV/HCV/NBNC | 30/170/62 |
Child Pugh classification | A/B/C | 147/93/22 |
Number of tumors | < 10/≥ 10 | 114/148 |
Maximum tumor size (mm) | Median (range) | 32.5 (8.0-300.0) |
Stage1 | I/II/III/IV | 17/45/136/64 |
PVTT grade | Vp0/Vp1-2/Vp3 | 202/27/33 |
Total bilirubin (mg/dL) | mean ± SD | 1.0 ± 0.7 |
Albumin (g/dL) | mean ± SD | 3.4 ± 0.6 |
Prothrombin time (%) | mean ± SD | 91.1 ± 8.4 |
Platelet count (× 104/L) | mean ± SD | 8.9 ± 5.0 |
AFP (ng/mL) | median (range) | 31.6 (1.0-1 000 000) |
AFP-L3 (ng/mL) | median (range) | 4.0 (0-91.8) |
DCP (mAU/mL) | median (range) | 60 (0-928 900) |
Previous treatment | Yes/no | 107/155 |
Data are expressed as median values with ranges, mean ± SD, or number of patients.
According to the modified RECIST (mRECIST) criteria. HBV: Hepatitis B virus; HCV: Hepatitis C virus; NBNC: Negative for hepatitis B surface antigen and HCV antibody; PVTT: Portal vein tumor thrombosis; AFP: α-fetoprotein; AFP-L3: Lens culinaris agglutinin-reactive fraction of α-fetoprotein; DCP: Des-γ-carboxy prothrombin.